期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 21, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/ijms21093057
关键词
HCV; HCC; epigenetics; signaling; tumor immunity; clinical impact
资金
- European Union [ERC-AdG-2014 HEPCIR ERC POC PRELICAN 755460, ERC POC HEPCAN 862551, EU H2020 HEPCAR 667273]
- French Cancer Agency [TheraHCC2.0 IHU201901299]
- Agence Nationale de Recherche sur le Sida et les hepatites virale [ANRS ECTZ103701]
- French Fondation pour la Recherche Medicale [FDT201805005763]
- National Institute (NIAID) [U19AI12386, R03AI13106]
- National Institute (NCI) [1R21CA209940]
- National Institute (NIDDK) [R01CA233794]
- Fondation de l'Universite de Strasbourg (HEPKIN) [TBA-DON-0002]
- Inserm Plan Cancer 2019-2023
- German Research Foundation [DFG-395783133]
- Initiative of excellence IDEX-Unistra [ANR-10-IDEX-0002-02]
- LABEX [ANR-10-LAB-28]
Chronic infection with hepatitis C virus (HCV) is a major cause of hepatocellular carcinoma (HCC). Novel treatments with direct-acting antivirals achieve high rates of sustained virologic response; however, the HCC risk remains elevated in cured patients, especially those with advanced liver disease. Long-term HCV infection causes a persistent and accumulating damage of the liver due to a combination of direct and indirect pro-oncogenic mechanisms. This review describes the processes involved in virus-induced disease progression by viral proteins, derailed signaling, immunity, and persistent epigenetic deregulation, which may be instrumental to develop urgently needed prognostic biomarkers and as targets for novel chemopreventive therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据